It is commonly investigated in preclinical research models relating to metabolic signalling pathways, cellular energy regulation, and enzymatic activity associated with nicotinamide N-methyltransferase (NNMT) interaction studies
Doses up to 1,000 mcg, though unnecessary, aren't harmful
Contact Smart Choice Medical Clinic in Tyler, TX, today to schedule your consultation
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
One study suggests that most people with SIRVA have symptoms for at least six months, and fewer than 1 in 3 make a full recovery
